In preclinical combination studies, CTLA-4 blockade has been shown to synergise with PARP inhibition in Brca1-deficient mouse models of ovarian cancer in a manner dependent on IFN-γ secretion into the TME (Higuchi et al, 2015). The gene discussed is BRCA1; the disease is ovarian carcinoma.